Humoral and cellular immune responses to CoronaVac assessed up to one year after vaccination.

ABSTRACT:

Background

The Sinovac SARS-CoV-2 inactivated vaccine (CoronaVac) has been demonstrated to be safe, well tolerated, and efficacious in preventing mild and severe Covid-19. Although different studies have demonstrated its short-term immunogenicity, long-term cellular and humoral response evaluations are still lacking.

Methods

Cellular and humoral responses were assessed after enrollment of volunteers in the PROFISCOV phase 3 double-blind, randomized, placebo-controlled clinical trial to evaluate CoronaVac. Assays were performed using flow cytometry to evaluate cellular immune response and an antigen binding electrochemiluminescence assay to detect antigen-specific antibodies to the virus.

Results

Fifty-three volunteers were selected for long term assessment of their SA

SUBMITTER: Costa PR 

PROVIDER: S-EPMC9275662 | biostudies-literature | 2022 Jul

REPOSITORIES: biostudies-literature